Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Erlangen – page 10

390 clinical trials in Erlangen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erlangen at a glance
390
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

390 trials in Erlangen

Open in trial search

Systemic scleroderma+2

Recruiting

Study on the Safety of MB-CART19.1 for Patients with Active Systemic Lupus Erythematosus, Systemic Sclerosis, or Dermatomyositis/Polymyositis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
  • Sponsor:Miltenyi Biomedicine GmbH

Diffuse large B-cell lymphoma

Recruiting

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Busulfan
  • Sponsor:Medical Center - University Of Freiburg

C3 glomerulopathy

Recruiting

Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Chronic lymphocytic leukaemia

Recruiting

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Acute myeloid leukaemia

Recruiting

Study of Gilteritinib, Venetoclax, and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutations Not Eligible for Intensive Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Technische Universitat Dresden

Seizure

Recruiting

Study on the Safety and Effectiveness of Alprazolam for Treating Long Seizures in Patients Aged 12 and Older

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alprazolam
  • Sponsor:UCB Biopharma

Chronic kidney disease

Recruiting

Study on the Effects of Dapagliflozin on Kidney Health in Patients with Chronic Kidney Disease After Kidney Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsklinikum Erlangen AöR

Haemorrhagic stroke

Recruiting

Study on Eptacog Alfa for Treating Acute Hemorrhagic Stroke in Patients with Brain Bleeding

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Eptacog Alfa (Activated)
  • Sponsor:University Of Cincinnati College Of Medicine

Medulloblastoma

Recruiting

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Breast cancer

Recruiting

Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Haemolytic uraemic syndrome

Recruiting

Study on the Effectiveness of INM004 for Children with Hemolytic Uremic Syndrome Caused by Shiga Toxin-Producing E. coli

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Equine immunoglobulin F(AB')2 fragments targeting shiga toxin
  • Sponsor:Chemo Research S.L.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Erlangen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of new therapies for HR-positive and HER2-negative variants. Additional research encompasses lung cancer and various lymphomas.

  • Advanced/Metastatic Breast Cancer Treatments
  • Non-small Cell Lung Cancer Therapy
  • Lymphoma Treatment Approaches

Studies evaluate novel therapeutic combinations and targeted treatments for improved patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, including lupus erythematosus, psoriasis, and systemic conditions. Studies focus on innovative therapeutic approaches.

  • Cutaneous Lupus Treatment
  • Plaque Psoriasis Management
  • Systemic Sclerosis Research

Trials aim to develop more effective treatments for chronic autoimmune conditions.

03 Neurological Disorders

Clinical investigations focusing on acute cerebral ischemic stroke and multiple system atrophy. Research emphasizes innovative therapeutic approaches for better patient outcomes.

  • Stroke Treatment Development
  • Multiple System Atrophy Management
  • Neurological Disease Interventions

Studies evaluate new therapeutic agents and treatment strategies for neurological conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.